An Evaluation of Ledipasvir + Sofosbuvir for the Treatment of Chronic Hepatitis C Infection

Overview

Journal Expert Opin Pharmacother

Publisher Informa Healthcare

Specialty Pharmacology

Date 2021 Jun 23

PMID 34157923

Authors

Pearson Balatow

Amber Sandlin

Theodore James Cory

Affiliations

Soon will be listed here.

Abstract

: Hepatitis C (HCV) is viral disease with a global impact. Over the last 10 years, the treatment of this disease has evolved. Treatment guidelines have evolved to adopt new medications for HCV. These drugs have shown efficacy over 90% throughout the class as well as a better safety profile than the previous recommended pharmacotherapy. Dual-therapy DAAs emerged with FDA approval of Ledipasvir/Sofosbuvir (LDV/SOF) in 2014.: LDV/SOF is a dual-therapy option for chronic HCV patients (>6 months of infection) in select genotypes. This article reviews the studies relevant to the pharmacokinetic/pharmacodynamic properties of these drugs as well as its trials leading to approval.: LDV/SOF is included in the AASLD/IDSA guidelines for the treatment of HCV genotypes 1a and 1b with or without cirrhosis and genotype 4 without cirrhosis with an evidence and recommendation rating of IA. Genotype 4 with cirrhosis and genotypes 5 and 6 carry a Class IIa level B recommendation. The combination is not FDA approved for genotypes 2 and 3. Single-pill regimens, like LDV/SOF, are important to maintain the quality of life of children and other special populations infected with HCV by shortening treatment regimens, avoiding complex pill regimens, and eliminating injection therapies.

References

Schneider E . Cytochrome P450 3A4 Induction: Lumacaftor versus Ivacaftor Potentially Resulting in Significantly Reduced Plasma Concentration of Ivacaftor. Drug Metab Lett. 2018; 12(1):71-74. PMC: 6350194. DOI: 10.2174/1872312812666180328105259. View

Gritsenko D, Hughes G . Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection. P T. 2015; 40(4):256-76. PMC: 4378517. View

Smolders E, Jansen A, Ter Horst P, Rockstroh J, Back D, Burger D . Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet. 2019; 58(10):1237-1263. PMC: 6768915. DOI: 10.1007/s40262-019-00774-0. View

Kowdley K, Gordon S, Reddy K, Rossaro L, Bernstein D, Lawitz E . Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014; 370(20):1879-88. DOI: 10.1056/NEJMoa1402355. View

German P, Mathias A, Brainard D, Kearney B . Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C. Clin Pharmacokinet. 2016; 55(11):1337-1351. DOI: 10.1007/s40262-016-0397-0. View

Pawlotsky J . Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology. 2016; 151(1):70-86. DOI: 10.1053/j.gastro.2016.04.003. View

Zhou S, Chan E, Pan S, Huang M, Lee E . Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol. 2004; 18(2):262-76. DOI: 10.1177/0269881104042632. View

Berenguer J, Alvarez-Pellicer J, Miralles Martin P, Lopez-Aldeguer J, Von-Wichmann M, Quereda C . Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009; 50(2):407-13. DOI: 10.1002/hep.23020. View

Fung A, Jin Z, Dyatkina N, Wang G, Beigelman L, Deval J . Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother. 2014; 58(7):3636-45. PMC: 4068585. DOI: 10.1128/AAC.02666-14. View

10.

Lawitz E, Poordad F, Pang P, Hyland R, Ding X, Mo H . Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2013; 383(9916):515-23. DOI: 10.1016/S0140-6736(13)62121-2. View

11.

Charlton M, Everson G, Flamm S, Kumar P, Landis C, Brown Jr R . Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015; 149(3):649-59. DOI: 10.1053/j.gastro.2015.05.010. View

12.

Chappell C, Scarsi K, Kirby B, Suri V, Gaggar A, Bogen D . Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study. Lancet Microbe. 2020; 1(5):e200-e208. PMC: 7491553. DOI: 10.1016/S2666-5247(20)30062-8. View

13.

Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner E . Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015; 313(12):1232-9. PMC: 7780246. DOI: 10.1001/jama.2015.1373. View

14.

German P, Mathias A, Brainard D, Kearney B . Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir. Clin Pharmacokinet. 2018; 57(11):1369-1383. DOI: 10.1007/s40262-018-0654-5. View

15.

Manns M, Samuel D, Gane E, Mutimer D, McCaughan G, Buti M . Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016; 16(6):685-697. DOI: 10.1016/S1473-3099(16)00052-9. View

16.

Ankrom W, Sanchez R, Yee K, Fan L, Mitra P, Wolford D . Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir. Antimicrob Agents Chemother. 2019; 63(5). PMC: 6496042. DOI: 10.1128/AAC.02491-18. View

17.

Denning J, Cornpropst M, Flach S, Berrey M, Symonds W . Pharmacokinetics, safety, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor for hepatitis C virus, following single ascending doses in healthy subjects. Antimicrob Agents Chemother. 2012; 57(3):1201-8. PMC: 3591883. DOI: 10.1128/AAC.01262-12. View

18.

Kuo M, Tseng C, Lee C, Yang Y, Wu H, Lin H . Identification and management of contraindicated drug-drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy. J Formos Med Assoc. 2021; 121(1 Pt 1):58-65. DOI: 10.1016/j.jfma.2021.01.008. View

19.

Vourvahis M, Kashuba A . Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy. 2007; 27(6):888-909. DOI: 10.1592/phco.27.6.888. View

20.

Afdhal N, Reddy K, Nelson D, Lawitz E, Gordon S, Schiff E . Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370(16):1483-93. DOI: 10.1056/NEJMoa1316366. View